Week in Review: Brady's bunch of thoughts | Prostate cancer staging gets a boost | Hybrid imaging of long COVID

Dear AuntMinnieEurope Member,

Dr. Adrian Brady is due to take over as president of the European Society of Radiology next month. What's occupying his mind? What are his areas of special interest?

Brady has shared his thoughts in an entertaining podcast, and we've summarized the contents for you in this week's top article. Find out more in the CT Community.

Prostate cancer staging is a rapidly evolving area, and PET/MRI is generating particular excitement. The results of a new study from the IRCCS Ospedale San Raffaele in Milan have been unveiled. Given the complex nature of research like this, it's understandable that the sample size was relatively small, but the findings still deserve a close look in our Molecular Imaging Community.

Another hot topic in hybrid imaging is PET/CT's role in tracking COVID-19 infection. At last week's Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, a team from India elaborated on how F-18 FDG PET/CT can help to evaluate post-COVID lung disease.

German groups appear to win the SNMMI's Image of the Year award on a regular basis, and investigators from Hannover Medical School collected the 2022 prize.

They used a gallium-68-labeled (Ga-68) radiotracer designed to bind to fibroblast cells (Ga-68 FAPI-46) and performed fibroblast-activation protein inhibitor (FAPI)-PET imaging in 35 patients several days after they experienced a heart attack. The team found that the FAPI-PET signal in injured heart muscle predicted heart dysfunction in patients more than four months later.

Last but definitely not least, MRI researchers from Imperial College London believe they've made significant progress in identifying early-stage Alzheimer's patients for clinical trials of new drug treatments or lifestyle changes. Also, their technique might make it simpler and quicker to make a diagnosis. Go to the MRI Community.

Page 1 of 1240
Next Page